Skip to main content

Advertisement

SpringerLink
Log in

Chemotherapy for advanced pancreatic cancer: Past, present, and future

  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

Advanced pancreatic cancer is a devastating illness characterized by significant morbidity and a brief median survival. Although standard chemotherapy with gemcitabine achieves only modest improvements in survival and quality of life, classic cytotoxic agents, such as 5-fluorouracil, pemetrexed, irinotecan, exatecan, cisplatin, or oxaliplatin, given alone or in combination with gemcitabine, have not proved superior. Thus, more recent trials have focused on targeting the biologic characteristics of pancreatic cancer. Although phase III trials of farnesyl transferase and matrix metalloproteinase inhibitors have not improved survival, encouraging preliminary results have been observed in phase II studies of inhibitors of the vascular endothelial growth factor and the epidermal growth factor receptor.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Jemal A, Tiwari RC, Murray T, et al.: Cancer statistics, 2004. CA Cancer J Clin 2004, 54:8–29.

    Article  PubMed  Google Scholar 

  2. Carter SK, Comis RL: The integration of chemotherapy into a combined modality approach for cancer treatment. VI. Pancreatic adenocarcinoma. Cancer Treat Rev 1975, 2:193–214.

    Article  PubMed  CAS  Google Scholar 

  3. Van Rijswijk RE, Jeziorski K, Wagener DJ, et al.: Weekly high-dose 5-fluorouracil and folinic acid in metastatic pancreatic carcinoma: a phase II study of the EORTC Gastrointestinal Tract Cancer Cooperative Group. Eur J Cancer 2004, 40:2077–2081.

    Article  PubMed  CAS  Google Scholar 

  4. Rubin J, Gallagher JG, Schroeder G, et al.: Phase II trials of 5-fluorouracil and leucovorin in patients with metastatic gastric or pancreatic carcinoma. Cancer 1996, 78:1888–1891.

    Article  PubMed  CAS  Google Scholar 

  5. Fung MC, Takayama S, Ishiguro H, et al.: [Chemotherapy for advanced or metastatic pancreatic cancer: analysis of 43 randomized trials in 3 decades (1974-2002)]. Gan To Kagaku Ryoho 2003, 30:1101–1111.

    PubMed  Google Scholar 

  6. Casper ES, Green MR, Kelsen DP, et al.: Phase II trial of gemcitabine (2,2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 1994, 12:29–34.

    Article  PubMed  CAS  Google Scholar 

  7. Rothenberg ML, Moore MJ, Cripps MC, et al.: A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol 1996, 7:347–353.

    PubMed  CAS  Google Scholar 

  8. Burris HA 3rd, Moore MJ, Andersen J, et al.: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997, 15:2403–2413. This classic phase III study of gemcitabine versus 5-FU was the first of many to support gemcitabine as the standard of care for advanced pancreatic cancer.

    PubMed  CAS  Google Scholar 

  9. Storniolo AM, Enas NH, Brown CA, et al.: An investigational new drug treatment program for patients with gemcitabine: results for over 3000 patients with pancreatic carcinoma. Cancer 1999, 85:1261–1268.

    Article  PubMed  CAS  Google Scholar 

  10. Tempero M, Plunkett W, Ruiz Van Haperen V, et al.: Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 2003, 21:3402–3408. A phase II trial of fixed dose rate gemcitabine modulation. This gemcitabine modulation strategy is currently being evaluated in an ECOG randomized phase III study versus 30-minute gemcitabine and GemOx.

    Article  PubMed  CAS  Google Scholar 

  11. Oliani C, Padovani M, Manno P, et al.: Gemcitabine and continuous infusion of 5-fluorouracil in locally advanced and metastatic pancreatic cancer: a phase I-II study. Anticancer Res 2004, 24:2107–2112.

    PubMed  CAS  Google Scholar 

  12. Correale P, Messinese S, Marsili S, et al.: A novel biweekly pancreatic cancer treatment schedule with gemcitabine, 5-fluorouracil and folinic acid. Br J Cancer 2003, 89:239–242.

    Article  PubMed  CAS  Google Scholar 

  13. Berlin JD, Catalano P, Thomas JP, et al.: Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 2002, 20:3270–3275.

    Article  PubMed  CAS  Google Scholar 

  14. Kindler HL, William D, Hochster H, et al.: Clinical outcome in patients (pts) with advanced pancreatic cancer treated with pemetrexed/gemcitabine [abstract]. Proc ASCO 2002, 21:499.

    Google Scholar 

  15. Richards DA, Kindler HL, Oettle H, et al.: A randomized phase III study comparing gemcitabine + pemetrexed versus gemcitabine in patients with locally advanced and metastatic pancreas cancer [abstract]. Proc ASCO 2004, 23:4007.

    Google Scholar 

  16. Cartwright TH, Cohn A, Varkey JA, et al.: Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer. J Clin Oncol 2002, 20:160–164.

    Article  PubMed  CAS  Google Scholar 

  17. Hess V, Salzberg M, Borner M, et al.: Combining capecitabine and gemcitabine in patients with advanced pancreatic carcinoma: a phase I/II trial. J Clin Oncol 2003, 21:66–68.

    Article  PubMed  CAS  Google Scholar 

  18. Scheithauer W, Schull B, Ulrich-Pur H, et al.: Biweekly highdose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial. Ann Oncol 2003, 14:97–104.

    Article  PubMed  CAS  Google Scholar 

  19. Okada S, Okusaka T, Ueno H, et al.: A phase II and pharmacokinetic trial of S-1 in patients with advanced pancreatic cancer. Proc Am Soc Clin Oncol 2002, 21:682.

    Google Scholar 

  20. Nakamura K, Yamaguchi T, Ishihara T, et al.: A phase I/II study of gemcitabine (GEM) with oral S-1 in metastatic pancreatic carcinoma [abstract]. Proc ASCO 2004, 23:4134.

    Google Scholar 

  21. Philip PA, Zalupski MM, Vaitkevicius VK, et al.: Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma. Cancer 2001, 92:569–577.

    Article  PubMed  CAS  Google Scholar 

  22. Heinemann V, Quietzsch D, Gieseler F, et al.: A phase III trial comparing gemcitabine plus cisplatin vs. gemcitabine alone in advanced pancreatic carcinoma [abstract]. Proc ASCO 2003, 22:1003.

    Google Scholar 

  23. Reni M, Passoni P, Panucci MG, et al.: Definitive results of a phase II trial of cisplatin, epirubicin, continuous-infusion fluorouracil, and gemcitabine in stage IV pancreatic adenocarcinoma. J Clin Oncol 2001, 19:2679–2686.

    PubMed  CAS  Google Scholar 

  24. Reni M, Cordio S, Passardi A, et al.: Final results of a phase III trial of gemcitabine (G) versus PEFG regimen in stage IVA or metastatic pancreatic adenocarcinoma (PA) [abstract]. Proc ASCO 2004, 23:4010.

    Google Scholar 

  25. Louvet C, Labianca R, Hammel P, et al.: GemOx (gemcitabine + oxaliplatin) versus Gem (gemcitabine) in non-resectable pancreatic adenocarcinoma: final results of the GERCOR / GISCAD Intergroup Phase III [abstract]. Proc ASCO 2004, 23:4008.

    Google Scholar 

  26. Rocha Lima CM, Green MR, Rotche R, et al.: Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 2004, 22:3776–3783.

    Article  PubMed  CAS  Google Scholar 

  27. Burtness B, Sipples R, Mirto G, et al.: Phase II trial of irinotecan/ docetaxel combination for advanced pancreatic cancer [abstract]. Proc ASCO 2004, 23:4116.

    Google Scholar 

  28. Cheverton P, Friess H, Andras C, et al.: Phase III results of exatecan (DX-8951f) versus gemcitabine (Gem) in chemotherapy-naïve patients with advanced pancreatic cancer (APC) [abstract]. Proc ASCO 2004, 23:4005.

    Google Scholar 

  29. O Reilly EM, Abou-Alfa GK, Letourneau R, et al.: A randomized phase III trial of DX-8951f (exatecan mesylate, DX) and gemcitabine (GEM) vs. gemcitabine alone in advanced pancreatic cancer (APC) [abstract]. Proc ASCO 2004, 23:4006.

    Google Scholar 

  30. Schneider BP, Ganjoo KN, Seitz DE, et al.: Phase II study of gemcitabine plus docetaxel in advanced pancreatic cancer: a Hoosier Oncology Group study. Oncology 2003, 65:218–223.

    Article  PubMed  CAS  Google Scholar 

  31. Kulke M, Niedzwiecki D, Tempero M, et al.: A randomized phase II study of gemcitabine/cisplatin, gemcitabine fixed dose rate infusion, gemcitabine/docetaxel, or gemcitabine/ irinotecan in patients with metastatic pancreatic cancer (CALGB 89904) [abstract]. Proc ASCO 2004, 23:4011.

    Google Scholar 

  32. Whitehead R, McCoy S, Rivkin S, et al.: A phase II trial of epothilone B analogue BMS-247550 (NSC #710428) in patients with advanced pancreas cancer: a Southwest Oncology Group Study [abstract]. Proc ASCO 2004, 23:4012.

    Google Scholar 

  33. Milella M, Gelibter A, Di Cosimo S, et al.: Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinoma. Cancer 2004, 101:133–138.

    Article  PubMed  CAS  Google Scholar 

  34. Van Laethem J, Polus M, Marechal R, et al.: Gemcitabine and oxaliplatine (GEMOX) in gemcitabine-refractory advanced pancreatic cancer: a phase II study. Proc ASCO 2004, 23:4119.

    Google Scholar 

  35. Pelzer U, Hempel C, Stieler J, et al.: Oxaliplatin (OXA) in combination with high dose 5-FU (24h)/folinic acid (FA) as salvage therapy in patients with gemzar-refractory advanced pancreatic cancer [abstract]. Proc ASCO 2002, 21:684.

    Google Scholar 

  36. Ulrich-Pur H, Raderer M, Verena Kornek G, et al.: Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma. Br J Cancer 2003, 88:1180–1184.

    Article  PubMed  CAS  Google Scholar 

  37. Jacobs A, Burris HA 3rd, Rivkin S, et al.: A randomized phase III study of rubitecan (ORA) vs best choice (BC) in 409 patients with refractory pancreatic cancer report from a North-American multi-center study [abstract]. Proc ASCO 2004, 23:4013.

    Google Scholar 

  38. Van Cutsem E, van de Velde H, Karasek P, et al.: Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 2004, 22:1430–1438.

    Article  PubMed  CAS  Google Scholar 

  39. Lersch C, Van Cutsem E, Amado R, et al.: Randomized phase II study of SCH 66336 and gemcitabine in the treatment of metastatic adenocarcinoma of the pancreas [abstract]. Proc ASCO 2001, 20:608.

    Google Scholar 

  40. Burch PA, Alberts SR, Schroeder MT, et al.: Gemcitabine and ISIS-2503 for patients with pancreatic adenocarcinoma (ACA): A North Central Cancer Treatment Group (NCCTG) phase II study [abstract]. Proc ASCO 2003, 22:1038.

    Google Scholar 

  41. Moore MJ, Hamm J, Dancey J, et al.: Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003, 21:3296–3302.

    Article  PubMed  CAS  Google Scholar 

  42. Bramhall SR, Schulz J, Nemunaitis J, et al.: A double-blind placebo-controlled, randomized study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 2002, 87:161–167.

    Article  PubMed  CAS  Google Scholar 

  43. Bramhall SR, Rosemurgy A, Brown PD, et al.: Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J Clin Oncol 2001, 19:3447–3455.

    PubMed  CAS  Google Scholar 

  44. Brett BT, Smith SC, Bouvier CV, et al.: Phase II study of anti-gastrin-17 antibodies, raised to G17DT, in advanced pancreatic cancer. J Clin Oncol 2002, 20:4225–4231.

    Article  PubMed  CAS  Google Scholar 

  45. Gilliam AD, Topuzov EG, Garin AM, et al.: Randomized, double blind, placebo-controlled, multi-center, groupsequential trial of G17DT for patients with advanced pancreatic cancer unsuitable or unwilling to take chemotherapy [abstract]. Proc ASCO 2004, 23:2511.

    Google Scholar 

  46. Seo Y, Baba H, Fukuda T, et al.: High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma. Cancer 2000, 88:2239–2245.

    Article  PubMed  CAS  Google Scholar 

  47. Itakura J, Ishiwata T, Shen B, et al.: Concomitant over-expression of vascular endothelial growth factor and its receptors in pancreatic cancer. Int J Cancer 2000, 85:27–34.

    Article  PubMed  CAS  Google Scholar 

  48. Kindler HL, Friberg G, Stadler WM, et al.: Bevacizumab (B) plus gemcitabine (G) in patient (pts) with advanced pancreatic cancer (PC): Updated results of a multi-center phase II trial [abstract]. Proc ASCO 2004, 23:4009. A phase II trial of the anti-VEGF antibody bevacizumab in combination with gemcitabine. This combination is currently being evaluated in a CALGB randomized phase III study.

    Google Scholar 

  49. Maples WJ, Stevenson J, Sumrall SV, et al.: Advanced pancreatic cancer: a multi-institutional trial with gemcitabine and thalidomide [abstract]. Proc ASCO 2004, 23:4082.

    Google Scholar 

  50. Williams CS, Tsujii M, Reese J, et al.: Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest 2000, 105:1589–1594.

    Article  PubMed  CAS  Google Scholar 

  51. Marini G, Simoncini E, Valcamonico F, et al.: Gemcitabine (Gem) plus celecoxib in advanced pancreatic carcinoma: a phase II study [abstract]. Proc ASCO 2004, 23:4103.

    Google Scholar 

  52. Xiong HQ, Rosenberg A, LoBuglio A, et al.: Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II trial. J Clin Oncol 2004, 22:2610–616. A phase II trial of the anti-EGFR antibody cetuximab in combination with gemcitabine. This combination is currently being evaluated in a SWOG randomized phase III study.

    Article  PubMed  CAS  Google Scholar 

  53. Safran H, Ramanathan R, Schwartz J, et al.: Herceptin and gemcitabine for metastatic pancreatic cancers that over-express HER-2/neu [abstract]. Proc ASCO 2001, 20:517.

    Google Scholar 

  54. Porterfield B, Dragovich T, Patnaik A, et al.: Erlotinib + gemcitabine in patients with unresectable pancreatic carcinoma: results from a phase IB trial [abstract]. Proc ASCO 2004, 23:4110.

    Google Scholar 

  55. OSI Pharmaceuticals I: Tarceva plus gemcitabine improves survival compared to gemcitabine alone in first-line pancreatic cancer patients. Press release. September 20, 2004.

  56. Hwang RF, Yokoi K, Bucana CD, et al.: Inhibition of plateletderived growth factor receptor phosphorylation by STI571 (Gleevec) reduces growth and metastasis of human pancreatic carcinoma in an orthotopic nude mouse model. Clin Cancer Res 2003, 9:6534–6544.

    PubMed  CAS  Google Scholar 

  57. Ebert M, Nitsche B, Roecken C, et al.: A prospective and randomized clinical trial of the tyrosine kinase inhibitor imatinib mesylate as an initial therapy of advanced pancreatic cancer [abstract]. Proc ASCO 2004, 23:4151.

    Google Scholar 

  58. Abdollahi A, Lipson KE, Sckell A, et al.: Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects. Cancer Res 2003, 63:8890–8898.

    PubMed  CAS  Google Scholar 

  59. Siu L, Takimoto C, Awada A, et al.: A phase I/II trial of BAY 43-9006 and gemcitabine in advanced solid tumors and in advanced pancreatic cancer [abstract]. Proc ASCO 2004, 23:3059.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Section of Hematology/Oncology, University of Chicago, 5841 S. Maryland Avenue, MC 2115, 60637-1470, Chicago, IL, USA

    Gregory Friberg MD & Hedy Lee Kindler MD

Authors
  1. Gregory Friberg MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hedy Lee Kindler MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Friberg, G., Kindler, H.L. Chemotherapy for advanced pancreatic cancer: Past, present, and future. Curr Oncol Rep 7, 186–195 (2005). https://doi.org/10.1007/s11912-005-0072-3

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11912-005-0072-3

Keywords

Search

Navigation